Direct-Acting Antiviral Therapy and Recurrence of Hepatitis C-Related Hepatocellular Carcinoma

Lower doses and shorter treatment regimens have the potential to reduce both physical and financial
Lower doses and shorter treatment regimens have the potential to reduce both physical and financial
The impact of direct-acting antiviral therapy was investigated in a large cohort of patients in complete remission following treatment of hepatitis C-related HCC.

According to results of a retrospective cohort study of patients with hepatitis C viral (HCV)-related hepatocellular carcinoma (HCC) who had achieved a complete response (CR) to anticancer treatment, subsequent direct-acting anti-hepatitis C viral therapy was not associated with recurrence of HCC. This study was published online in Gastroenterology.

Previous research had shown an association between achievement of a sustained hepatitis C viral response with interferon-based therapy administered following curative treatment for HCC and a decreased likelihood of disease recurrence. The current study was conducted to investigate whether direct-acting antiviral therapy administered in the same setting had an impact on the recurrence of disease in this population.

A total of 793 patients from 31 different sites in the United States and Canada who had achieved a complete response (CR) following treatment for HCV-related HCC during the period of 2013 to 2017 were included in the analysis. The percentages of patients who had or had not received subsequent direct-acting antiviral therapy were 38.3% and 61.7%, respectively. The HCC recurrence rate was 42.1% in the former group and 58.9% in the latter group.

After taking into account specific patient-, disease- and treatment-related factors, no association between direct-acting antiviral therapy and overall HCC recurrence (hazard ratio=0.90; 95% confidence interval [CI], 0.70–1.16) or early HCC recurrence (hazard ratio=0.96; 95% CI, 0.70–1.34) was observed.

Related Articles

“Our results suggest use of direct-acting antiviral therapies is safe and potentially beneficial in hepatitis-C–infected patients with a history of HCC,” the authors concluded.


  1. Singal AG, Rich NE, Mehta N, et al. Direct-Acting antiviral therapy not associated with recurrence of hepatocellular carcinoma in a multicenter North American cohort study [published online on January 17, 2019]. Gastroenterology. doi: 10.1053/j.gastro.2019.01.027

This article originally appeared on Cancer Therapy Advisor